34 hours ago · The incidence of myocardial toxicity increases after a total cumulative dose exceeding 400 to 550 mg/m 2 in adults, 300 mg/m 2 in children more than 2 years of age, or 10 mg/kg in children less than 2 years of age. Severe myelosuppression occurs when used in therapeutic doses; this may lead to infection or hemorrhage. >> Go To The Portal
Your doctor will check your heart function before you may take any daunorubicin and will monitor your heart closely during your treatment. Dose-related heart problems can occur as late as 7 or 8 years after treatments have ended.
Daunorubicin hydrochloride in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Daunorubicin hydrochloride injection is contraindicated in patients who have shown a hypersensitivity to it. Daunorubicin hydrochloride is a potent bone marrow suppressant. Suppression will occur in all patients given a therapeutic dose of this drug.
Physician must be capable of responding rapidly to severe hemorrhagic conditions or overwhelming infection. Administer daunorubicin into a rapidly flowing IV infusion. Severe local tissue necrosis will result if extravasation occurs. Do not administer IM or SC.
Daunorubicin may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:nausea.vomiting.sores in the mouth and throat.diarrhea.stomach pain.hair loss.red urine.
More commonBone or joint pain.general feeling of tiredness or weakness.heartburn or belching.itching or stinging at the injection site.loss of strength or energy.muscle aches or weakness.skin pain.stomach discomfort, upset, pain, or swelling.
This medicine may cause irreversible heart muscle damage, leading to heart failure. This is more likely to occur if you have other heart problems, have had or currently receiving radiation therapy to your chest, or have received other cancer medicines.
Daunorubicin is used to treat leukemia and other cancers. It belongs to a class of drugs known as anthracyclines and works by slowing or stopping the growth of cancer cells.
It is very important that your doctor check the blood of you or your child on a regular basis while you are using this medicine. You may also need to monitor your blood pressure at home. If you notice any changes to your recommended blood pressure, call your doctor right away. .
Commonly reported side effects of epoetin alfa include: upper respiratory tract infection, arthralgia, decreased serum iron, diarrhea, edema, fever, low serum ferritin, paresthesia, respiratory congestion, skin rash, tachycardia, cough, dyspnea, headache, nausea, signs and symptoms of injection site, and vomiting.
Your doctor will check your heart function (with an ECHO test) before you may take any Doxorubicin and will monitor your heart closely during your treatment. Dose-related heart problems can occur as late as 7 or 8 years after treatments have ended.
Doxorubicin extravasation during intravenous administration can result in severe tissue ulceration and necrosis, which worsens over time. Doxorubicin is also associated with significant cardiac toxicity, which limits the long-term use of the drug.
If you experience any of the following symptoms, call your doctor immediately: shortness of breath; difficulty breathing; swelling of the hands, feet, ankles or lower legs; or fast, irregular, or pounding heartbeat.
Daunorubicin is given by intravenous injection (IV). The syringe needle is placed directly into the tubing of a freely flowing IV solution into a vein or central line and the drug is given over several minutes. There is no pill form of daunorubicin.
Daunorubicin can only be administered intravenously through rapidly flowing infusions. Its administration cannot be subcutaneous or intramuscular as it can cause severe local tissue necrosis through the extravasation of the drug into the surrounding tissue.
Methotrexate may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:dizziness.drowsiness.headache.swollen, tender gums.decreased appetite.reddened eyes.hair loss.
Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action. Daunorubicin forms complexes with DNA by int...
Daunorubicin hydrochloride in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemi...
Parenteral drug products should be inspected visually for particulate matter prior to administration, whenever solution and container permit.
Daunorubicin Hydrochloride Injection, 5 mg/mL, is available as a deep red sterile liquid in butyl-rubber-stoppered vials as follows:NDC 0143-9551-1...
Daunorubicin forms complexes with DNA by intercalation between base pairs. It inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. Single strand and double strand DNA breaks result.
In the treatment of adult acute nonlymphocytic leukemia, Daunorubicin hydrochloride, used as a single agent, has produced complete remission rates of 40 to 50%, and in combination with cytarabine, has produced complete remission rates of 53 to 65%.
Daunorubicin hydrochloride is the hydrochloride salt of an anthracycline cytotoxic antibiotic produced by a strain of Streptomyces coeruleorubidus. It is provided as a deep red sterile liquid in vials for intravenous administration only.
The use of Daunorubicin hydrochloride in combination with vincristine, prednisone, and L-asparaginase has produced complete remission rates of 83% in contrast to a 47% remission in patients not receiving Daunorubicin hydrochloride.
Thereafter, plasma levels decline slowly with a half-life of 45 minutes in the initial phase and 18.5 hours in the terminal phase.
Daunorubicin hydrochloride may cause fetal harm when administered to a pregnant woman. An increased incidence of fetal abnormalities (parieto-occipital cranioschisis, umbilical hernias, or rachischisis) and abortions was reported in rabbits at doses of 0.05 mg/kg/day or approximately 1/100th of the highest recommended human dose on a body surface area basis. Rats showed an increased incidence of esophageal, cardiovascular and urogenital abnormalities as well as rib fusions at doses of 4 mg/kg/day or approximately 1/2 the human dose on a body surface area basis. Decreases in fetal birth weight and post-delivery growth rate were observed in mice. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.
Daunorubicin hydrochloride is a potent bone marrow suppressant. Suppression will occur in all patients given a therapeutic dose of this drug. Therapy with Daunorubicin hydrochloride should not be started in patients with pre-existing drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk. Persistent, severe myelosuppression may result in superinfection or hemorrhage.
Daunorubicin comes as a solution (liquid) or as a powder to be mixed with liquid to be injected intravenously (into a vein) by a doctor or nurse in a medical facility along with other chemotherapy medications.
Expand Section. Daunorubicin is used with other chemotherapy drugs to treat a certain type of acute myeloid leukemia (AML; a type of cancer of the white blood cells). Daunorubicin is also used with other chemotherapy drugs to treat a certain type of acute lymphocytic leukemia (ALL; a type of cancer of the white blood cells).
If you experience any of the following symptoms, call your doctor immediately: shortness of breath; difficulty breathing; swelling of the hands, feet, ankles or lower legs; or fast, irregular, or pounding heartbeat. Daunorubicin can cause a severe decrease in the number of blood cells in your bone marrow.
Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately: 1 redness, pain, swelling, or burning at the site where the injection was given 2 rash 3 hives 4 itching 5 difficulty breathing or swallowing
Daunorubicin may increase the risk that you will develop other cancers. Talk to your doctor about the risks of taking this medication. Daunorubicin may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.
Your doctor may need to adjust your dose if you have kidney or liver disease. Keep all appointments with your doctor and the laboratory. Your doctor will order certain tests to check your body's response to daunorubicin.
Expand Section. Daunorubicin injection must be given in a hospital or medical facility under the supervision of a doctor who is experienced in giving chemotherapy medications for cancer. Daun orubicin may cause serious or life-threatening heart problems at any time during your treatment or months to years after your treatment has ended.
What is daunorubicin? Daunorubicin (also called daunomycin or Cerubidine®) is an anticancer medicine. Daunorubicin is a red liquid given into a vein (IV). Daunorubicin can pose a health hazard to caregivers.
Daunorubicin can cause nausea and vomiting. The doctor may prescribe medicine to keep you from feeling sick and throwing up after you receive daunorubicin. Tell the nurse right away if you have pain or redness at the IV site. Drink plenty of liquids while you are receiving daunorubicin.
The doctor or nurse may give you oral rinses to keep your mouth clean after you receive daunorubicin. Blood will be drawn regularly to check for changes in kidney or liver function and to check blood counts. Tests to check your heart function might be done while you receive daunorubicin.
The drug should be administered under the supervision of an experienced leukemia-chemotherapy physician. Physician must be capable of responding rapidly to severe hemorrhagic conditions or overwhelming infection.
Anthracycline; intercalates between DNA base pairs, impairs topoisomerase II function and subsequently inhibits DNA and RNA replication
Y-site: allopurinol, aztreonam, cefepime, fludarabine, piperacillin/tazobactam
WARNING: Daunorubicin must be given only by injection into a vein. This medication must not be given by injection into a muscle or under the skin. If this medication accidentally leaks into the skin/muscle around the injection site, it may cause severe damage.
Adding plans allows you to compare formulary status to other drugs in the same class.
Daunorubicin works by preventing the growth of cancer cells and eventually destroying them. It is used to treat different types of cancers including the following types of cancers:
Daunorubicin (as hydrochloride). Each vial of Pfizer (Perth) Daunorubicin contains 2.14 mg/mL daunorubicin hydrochloride (equivalent to 2 mg/mL daunorubicin). For the full list of excipients, see Section 6.1 List of Excipients. Solution for injection.
The plasma half-life of daunorubicin averages 45 minutes in the initial phase and 18.5 hours in the terminal phase. By one hour after administration of daunorubicin, the predominant form of the drug in plasma is the metabolite daunorubicinol, which has as average terminal plasma half-life of 26.7 hours.
Extravasation of daunorubicin at the site of intravenous administration can cause local pain, severe tissue lesions (vesication, severe cellulitis) and necrosi s. Should signs or symptoms of extravasation occur during intravenous administration of daunorubicin, the drug infusion should be immediately stopped.
Daunorubicin should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents. It is recommended the injection be added to a free flowing IV infusion of 0.9% sodium chloride or 5% dextrose injection.
Daunorubicin has been used in all stages, alone or in combination with other cytotoxic agents (e.g. cytarabine). Disseminated solid tumours. Daunorubicin has been investigated for use in these tumours and found to be effective in some cases of disseminated neuroblastoma and rhabdomyosarcoma.
If you think you may have been given too much Daunorubicin, immediately telephone your doctor or the Poisons Information Centre (Phone Australia 13 11 26) for advice or go to Accident and Emergency at your nearest hospital. Ask your doctor if you have any concerns.
Only professionals, who have been trained in the safe use of the preparation of chemotherapeutic agents, should prepare daunorubicin for administration .
Daunorubicin is extensively metabolised in the liver and other tissues , mainly by cytoplasmic aldo-keto reductases, producing daunorubicinol, the major metabolite, which has antineoplastic activity. Approximately 40% of the drug in the plasma is present as daunorubicinol within 30 minutes and 60% in 4 hours after a dose of daunorubicin. Additional metabolism by reductive cleavage of the glycosidic bond produces aglycones, which have little or no cytotoxic activity and are demethylated and conjugated with sulphate and glucuronide by microsomal enzymes.
Secondary leukaemia, with or without a preleukemic phase, has been reported in patients treated with anthracyclines, including daunorubicin. Secondary leukaemia is more common when such drugs are given in combination with DNA-damaging antineoplastic agents, in combination with radiotherapy, when patients have been heavily pre-treated with cytotoxic drugs, or when doses of the anthracyclines have been escalated. These leukemias can have a 1- to 3-year latency period.
Due to its immunosuppressive properties, concurrent use of daunorubicin with a live virus vaccin e may potentiate the replication of the vaccine, increase the adverse effects of the vaccine virus, or decrease the patient’s antibody response to the virus.
Complete alopecia involving beard growth and the scalp, axillary and pubic hair occurs almost always with full doses of daunorubicin. This side-effect may cause distress to patients but is usually reversible, with regrowth of hair, which usually occurs within two to three months from the termination of therapy.
Phlebosclerosis may result from an injection into a small vessel or from repeated injections into the same vein. Following the recommended administration procedures may minimise the risk of phlebitis/thrombophlebitis at the injection site (see section 4.2 Dose and method of administration).
Daunorubicin may enhance the toxicity of other cytotoxic agents when administered concurrently and dosage should be suitably reduced (see section 4.5 Interactions with other medicines and other forms of interactions).